Instrument Inactif

Communiqués Soligenix Inc OTC Bulletin Board

Actions

US8342233074

Recherche biotechnologique et médicale

Communiqués

08/05	Soligenix Announces Recent Updates and First Quarter 2026 Financial Results	PR
23/03	Soligenix : HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026	PU
19/03	IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.	AQ
19/12	Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behcet's Disease Published in Rheumatology (Oxford)	AQ
17/12	Soligenix : Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis	PU
05/12	Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad	GL
03/12	Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space	GL
19/09/25	Soligenix : Corporate Presentation	PU
02/09/25	Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference	PR
19/08/25	FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behcet's Disease after Reviewing Recent Phase 2 Clinical Study Results	AQ
18/08/25	FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results	PR
14/08/25	Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results	PR
08/08/25	NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer	AQ
07/08/25	Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy	GL
05/08/25	Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space	GL
05/08/25	Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space	AQ
01/08/25	Soligenix, Inc. - Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behcet's Disease	AQ
31/07/25	Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease	PR
08/07/25	Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones	PR
01/07/25	Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions	PR
06/06/25	Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials	AQ
09/05/25	Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results	PR
05/05/25	Soligenix Issues Interim Results For CTCL Treatment Trial 75% Response At 18 Weeks, 3 Patients Achieve Complete Response	AQ
24/04/25	Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding	AQ
15/04/25	Soligenix, Inc. - Positive Outcome in 75% of CTCL Patients Treated with HyBryte for 18 Weeks	AQ